CSCI — COSCIENS Biopharma Share News
0.000.00%
Last trade - 00:00- CA$9.55m
- CA$4.91m
- $7.50m
Brief: Aeterna Zentaris Outlines Progress On Development Pipeline Programs
Brief: Aeterna Zentaris Reports First Quarter 2023 Financial Results
Aeterna falls on suspending US sales of growth hormone deficiency drug
Brief: Aeterna Zentaris Provides Update On Macrilen® (Macimorelin), Reiterates Advancement Of Pediatric Detect Trial
Advisory: Incorrect alerts on Aeterna Zentaris Q4 results withdrawn
Brief: Aeterna Zentaris Inc - QTRLY Net Loss Of $12.5 Million, Or $2.56 Loss Per Common Share
Aeterna rises on plans to discontinue early-stage vaccine development program
Brief: Aeterna Zentaris Provides Business Update
Brief: Aeterna Zentaris Reports Q3 2022 Financial Results
Brief: Aeterna Zentaris Set To Regain Full Rights To Macrilen In U.S. And Canada From Novo Nordisk
Brief: Aeterna Zentaris Reports Q2 Rev Negative $0.2 Mln
Brief: Aeterna Zentaris Reports Shareholder Approval Of Share Consolidation
Brief: Aeterna Zentaris Achieves Proof-Of-Concept For The Treatment Of Nmosd With Aim Biologicals Program
Brief: Aeterna Provides Update On Pre-Clinical Results From AIM Biologicals Development Program
Brief: Aeterna Zentaris Reports First Quarter 2022 Financial Results
Brief: Aeterna Zentaris Secures European Patent Related To Use Of Macimorelin
Brief: Aeterna Zentaris Reports Quarterly Results, Provides Business Outlook
Aeterna slips after drug study to diagnose hormone deficiency faces delays
Brief: Aeterna Zentaris Provides Update On Ongoing Pivotal Phase 3 Detect-Trial For Diagnosis Of Childhood-Onset Growth Hormone Deficiency